Vanguard Personalized Indexing Management LLC Acquires 1,434 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Vanguard Personalized Indexing Management LLC increased its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 36.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,380 shares of the biopharmaceutical company’s stock after buying an additional 1,434 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Intra-Cellular Therapies were worth $385,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Xponance Inc. increased its holdings in shares of Intra-Cellular Therapies by 3.0% in the 4th quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock valued at $407,000 after acquiring an additional 163 shares during the period. Regal Investment Advisors LLC raised its holdings in Intra-Cellular Therapies by 1.4% in the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 186 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Intra-Cellular Therapies by 0.8% during the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock valued at $1,396,000 after buying an additional 200 shares during the last quarter. Bailard Inc. lifted its position in shares of Intra-Cellular Therapies by 1.2% during the fourth quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock valued at $1,223,000 after buying an additional 200 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of Intra-Cellular Therapies by 85.7% in the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 239 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Insider Activity

In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the transaction, the executive vice president now owns 16,170 shares in the company, valued at $1,076,275.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Suresh K. Durgam sold 6,450 shares of Intra-Cellular Therapies stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Halstead sold 7,345 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.97, for a total transaction of $484,549.65. Following the transaction, the executive vice president now owns 19,803 shares of the company’s stock, valued at $1,306,403.91. The disclosure for this sale can be found here. Insiders have sold 168,487 shares of company stock worth $11,364,950 in the last ninety days. Company insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Trading Down 1.3 %

Shares of NASDAQ:ITCI opened at $65.54 on Friday. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89. The business has a 50 day moving average of $68.89 and a two-hundred day moving average of $67.14. The company has a market capitalization of $6.92 billion, a PE ratio of -56.50 and a beta of 1.01.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The firm had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. During the same period in the prior year, the firm posted ($0.46) earnings per share. The firm’s quarterly revenue was up 52.0% compared to the same quarter last year. Equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ITCI. Bank of America increased their target price on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. The Goldman Sachs Group raised their price objective on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 17th. Mizuho upped their target price on Intra-Cellular Therapies from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Monday, April 22nd. Robert W. Baird increased their price target on Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Finally, TD Cowen boosted their price target on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $90.17.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.